Effect of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiogram substudy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F11%3A33148888" target="_blank" >RIV/61989592:15110/11:33148888 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1093/eurheartj/ehr311" target="_blank" >http://dx.doi.org/10.1093/eurheartj/ehr311</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/eurheartj/ehr311" target="_blank" >10.1093/eurheartj/ehr311</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiogram substudy

Popis výsledku v původním jazyce

Aims The SHIFT echocardiographic substudy evaluated the effects of ivabradine on left ventricular (LV) remodelling in heart failure (HF). Methods and results Eligible patients had chronic HF and systolic dysfunction [LV ejection fraction (LVEF) ?35%], were in sinus rhythm, and had resting heart rate ?70 bpm. Patients were randomly allocated to ivabradine or placebo, superimposed on background therapy for HF. Complete echocardiographic data at baseline and 8 months were available for 411 patients (ivabradine 208, placebo 203). Treatment with ivabradine reduced LVESVI (primary substudy endpoint) vs. placebo [?7.0 +- 16.3 vs. ?0.9 +- 17.1 mL/m2; difference (SE), ?5.8 (1.6), 95% CI ?8.8 to ?2.7, P{ 0.001]. The reduction in LVESVI was independent of beta-blocker use, HF aetiology, and baseline LVEF. Ivabradine also improved LV end-diastolic volume index (?7.9 +- 18.9 vs. ?1.8 +- 19.0 mL/m2, P= 0.002) and LVEF (+2.4 +- 7.7 vs. ?0.1 +- 8.0%, P{ 0.001). The incidence of the SHIFT primary compo

Název v anglickém jazyce

Effect of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiogram substudy

Popis výsledku anglicky

Aims The SHIFT echocardiographic substudy evaluated the effects of ivabradine on left ventricular (LV) remodelling in heart failure (HF). Methods and results Eligible patients had chronic HF and systolic dysfunction [LV ejection fraction (LVEF) ?35%], were in sinus rhythm, and had resting heart rate ?70 bpm. Patients were randomly allocated to ivabradine or placebo, superimposed on background therapy for HF. Complete echocardiographic data at baseline and 8 months were available for 411 patients (ivabradine 208, placebo 203). Treatment with ivabradine reduced LVESVI (primary substudy endpoint) vs. placebo [?7.0 +- 16.3 vs. ?0.9 +- 17.1 mL/m2; difference (SE), ?5.8 (1.6), 95% CI ?8.8 to ?2.7, P{ 0.001]. The reduction in LVESVI was independent of beta-blocker use, HF aetiology, and baseline LVEF. Ivabradine also improved LV end-diastolic volume index (?7.9 +- 18.9 vs. ?1.8 +- 19.0 mL/m2, P= 0.002) and LVEF (+2.4 +- 7.7 vs. ?0.1 +- 8.0%, P{ 0.001). The incidence of the SHIFT primary compo

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Heart Journal (print)

ISSN

0195-668X

e-ISSN

—

Svazek periodika

32

Číslo periodika v rámci svazku

20

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

2507-2515

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—